Clinical Trial Results:
Ultrasoundguided Transmuscular Quadratus Lumborum(TQL) block for percutaneous nephrolithotomy (PNL) - a randomized controlled trial
Summary
|
|
EudraCT number |
2015-004770-16 |
Trial protocol |
DK |
Global end of trial date |
30 Nov 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Dec 2019
|
First version publication date |
18 Dec 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
PNL_protocol_v01
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Zealand university hospital Roskilde
|
||
Sponsor organisation address |
Sygehus vej 10, Roskilde, Denmark, 4000
|
||
Public contact |
Jens Børglum, Dept of Anest. Copenhagen University Hospital - Roskilde, +45 30700120, jedn@regionsjaelland.dk
|
||
Scientific contact |
Jens Børglum, Dept of Anest. Copenhagen University Hospital - Roskilde, +45 30700120, jedn@regionsjaelland.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Apr 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Nov 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate whether a unilateral USG TQL block can reduce opioid consumption with clinical significance in PNL-patients.
|
||
Protection of trial subjects |
All patients received thoroughly information prior to inclusion. They all received a PCA pump in the postoperative period
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Aug 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 60
|
||
Worldwide total number of subjects |
60
|
||
EEA total number of subjects |
60
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
43
|
||
From 65 to 84 years |
17
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
All patient scheduled for elective PNL operation were invited to participate in the study.the patients were screened for inclusion and exclusion criteria. Thereafter the patients received oral and written information prior to enrollment. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Investigator, Monitor, Subject, Assessor | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Active | |||||||||||||||||||||
Arm description |
Unilateral TQL block with 0.75% ropivacaine 30 ml | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Ropivacaine
|
|||||||||||||||||||||
Investigational medicinal product code |
45010
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||
Routes of administration |
Other use
|
|||||||||||||||||||||
Dosage and administration details |
30 ml 0.75% ropivacain injected between QL and PM muscle
|
|||||||||||||||||||||
Arm title
|
Control | |||||||||||||||||||||
Arm description |
Received a TQL block with 30 ml of saline | |||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||
Investigational medicinal product name |
Sodium chloride
|
|||||||||||||||||||||
Investigational medicinal product code |
B05BB01
|
|||||||||||||||||||||
Other name |
Saline
|
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||||||||||||||
Routes of administration |
Other use
|
|||||||||||||||||||||
Dosage and administration details |
30 ml saline 0.9% injected between QL and PM muscle
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Active
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Unilateral TQL block with 0.75% ropivacaine 30 ml | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Control
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Received a TQL block with 30 ml of saline | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Active
|
||
Reporting group description |
Unilateral TQL block with 0.75% ropivacaine 30 ml | ||
Reporting group title |
Control
|
||
Reporting group description |
Received a TQL block with 30 ml of saline |
|
||||||||||
End point title |
OME 0-6 postoperative hours | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
0-6 hours
|
|||||||||
|
||||||||||
Statistical analysis title |
t- test | |||||||||
Comparison groups |
Control v Active
|
|||||||||
Number of subjects included in analysis |
51
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
< 0.001 | |||||||||
Method |
t-test, 2-sided | |||||||||
Confidence interval |
|
||||||||||||||||
Adverse events information [1]
|
||||||||||||||||
Timeframe for reporting adverse events |
24 hours
|
|||||||||||||||
Assessment type |
Systematic | |||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||
Dictionary version |
10.0
|
|||||||||||||||
Reporting groups
|
||||||||||||||||
Reporting group title |
Any events
|
|||||||||||||||
Reporting group description |
- | |||||||||||||||
Reporting group title |
Overall
|
|||||||||||||||
Reporting group description |
- | |||||||||||||||
|
||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||
|
||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: There were no adverse events reported regarding ropivacaine |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/31153628 |